[1] ROBERTSON K D，JONES P A. DNA methylation： past，present and future directions[J] .Carcinogenesis，2000，21(3)：461-467. [2] FINNEGAN E J，PEACOCK W J，DENNIS E S. DNA methylation，a key regulator of plant development and other processes[Ｊ] . Curr Opin Genet Dev，2000，10(2)：217-223. [3] GUTIERREZ J C，CALLEJAS S，BORNIQUEL S，et al. DNA methylation in ciliates： implications in differentiation processes[Ｊ] . Int Microbiol，2000，3(3)：139-146. [4] REIK W，DEAN W. DNA methylation and mammalian epigenetics[J] . Electrophoresis，2001，22(14)：2838-2843. [5] CHEN T，LI E. Structure and function of eukaryotic DNA methyltransferases[Ｊ] .Curr Top Dev Biol，2004，60：55-89. [6] BESTOR T H. The DNA methyltransferases of mammals[Ｊ] . Hum Mol Genet，2000，9(16)：2395-2402. [7] LIU K，WANG Y F，CANTEMIR C，et al. Endogenous assays of DNA methyltransferases： Evidence for differential activities of DNMT1，DNMT2，and DNMT3 in mammalian cells in vivo[Ｊ] . Mol Cell Biol，2003，23(8)：2709-2719. [8] ANTEQUERA F. Structure，function and evolution of CpG island promoters[Ｊ] . Cell Mol Life Sci，2003，60(8)：1647-1658. [9] GARINIS G A，PATRINOS G P，SPANAKIS N E，et al. DNA hypermethylation： when tumour suppressor genes go silent[Ｊ] . Hum Genet，2002，111(2)：115-127. [10] HERMAN J G，LATIF F，WENG Y， et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma[Ｊ] . Proc Natl Acad Sci USA，1994，91(21)：9700-9704. [11] OTTERSON G A，KHLEIF S N，CHEN W，et al. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine[J] .Oncogene，1995，11(6)：1211-1216. [12] LO K W，CHEUNG S T，LEUNG S F，et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma[J] .Cancer Res，1996，56(12)：2721-2725. [13] WONG D J，BARRETT M T，STOGER R，et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas[Ｊ] . Cancer Res，1997，57(13)：2619-2622. [14] YOSHIURA K，KANAI Y，OCHIAI A，et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas[J] .Proc Natl Acad Sci USA，1995，92(16)：7416-7419. [15] HERMAN J G，UMAR A，POLYAK K，et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma[Ｊ] . Proc Natl Acad Sci USA，1998，95(12)：6870-6875. [16] KANG G H，SHIM Y H，RO J Y.Correlation of methylation of the hMLH1 promoter with lack of expression of hMLH1 in sporadic gastric carcinomas with replication error[J] .Oncogene，1999，79(7)：903-909. [17] MAGDINIER F，BILLARD L M，WITTMANN G，et al. Regional methylation of the 5′ end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells[Ｊ] . FASEB J，2000，14(11)：1585-1594. [18] CAMERON E E，BAYLIN S B，HERMAN J G. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing[Ｊ] . Blood，1999，94(7)：2445-2451. [19] KAWANO S，MILLER C W，GOMBART A F. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation[Ｊ] . Blood，1999，94(3)：1113-1120. [20] GREGER V，DEBUS N，LOHMANN D，et al. FrequenCyAnd parental origin of hypermethylated RB1 alleles in retinoblastoma[J] . Hum Genet，1994，94(5)：491-496. [21] HILTUNEN M O，ALHONEN L，KOISTINAHO J，et al. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma[J] .Int J Cancer，1997，70(6)：644-648. [22] SHIN J Y，KIM H S，PARK J，et al. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells[Ｊ] . Cancer Res，2000，60(2)：262-265. [23] BENDER C M，PAO M M，JONES P A. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines[Ｊ] . Cancer Res，1998，58(1)：95-101. [24] BIGEY P，KNOX J D，CROTEAU S，et al. Modified oligonucleotides as bona fide antagonists of proteins interacting with DNA. Hairpin antagonists of the human DNA methyltransferase[Ｊ] .J Biol Chem，1999，274(8)：4594-4606. [25] CROOKE S T. Potential roles of antisense technology in cancer chemotherapy[J] .Oncogene，2000，19(56)：6651-6659. [26] MACLEOD A R，SZYF M. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis[Ｊ] . J Biol Chem，1995，270(14)：8037-8043. [27] GILES F J. New drugs in acute myeloid leukemia[J] .Curr Oncol Rep，2002，4(5)：369-374. [28] SANTINI V，KANTARJIAN H M，ISSA J P. Changes in DNA methylation in neoplasia： pathophysiology and therapeutic implications[Ｊ] . Ann Intern Med，2001，134(7)：573-586. [29] MCCREDIE K B，BODEY G P，BURGESS M A，et al. Treatment of acute leukemia with 5-azacytidine (NSC-102816)[J] .Cancer Chemother Rep，1973，57(3)：319-323. [30] KARON M，SIEGER L，LEIMBROCK S，et al. 5-Azacytidine： a new active agent for the treatment of acute leukemia[Ｊ] . Blood，1973，42(3)：359-365. [31] VON HOFF D D，SLAVIK M，MUGGIA F M. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia[Ｊ] . Ann Intern Med，1976，85(2)：237-245. [32] VOGLER W R，MILLER D S，KELLER J W. 5-Azacytidine (NSC 102816)： a new drug for the treatment of myeloblastic leukemia[Ｊ] . Blood，1976，48(3)：331-337. [33] RIVARD G E，MOMPARLER R L，DEMERS J，et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia[Ｊ] . Leuk Res，1981，5(6)：453-462. [34] MOMPARLER R L，RIVARD G E，GYGER M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia[Ｊ] . Pharmacol Ther，1985，30(3)：277-286. [35] WILLEMZE R，SUCIU S，ARCHIMBAUD E，et al. A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia： an EORTC Leukemia Cooperative Group phase II study (06893)[Ｊ] .Leukemia，1997，11(Suppl)1：S24-27. [36] SCHIFFER C A，DEBELLIS R，KASDORF H，et al. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213[Ｊ] . Cancer Treat Rep，1982，66(2)：267-271. [37] DUTCHER J P，EUDEY L，WIERNIK P H，et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia： a study of the eastern cooperative oncology group[J] . Leukemia，1992，6(8)：770-775. [38] KANTARJIAN H M，O′BRIEN S M，KEATING M，et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia[Ｊ] . Leukemia，1997，11(10)：1617-1620. [39] SACCHI S，KANTARJIAN H M，O′BRIEN S，et al. Chronic myelogenous leukemia in nonlymphoid blastic phase： analysis of the results of first salvage therapy with three different treatment approaches for 162 patients[Ｊ] . Cancer，1999，86(12)：2632-2641. [40] SILVERMAN L R. American society of clincal oncology 34th meeting，Los Angeles [D] . Preceeding of American Society of Clinical Oncology，1998，17：14a. [41] SILVERMAN L R，HOLLAND J F，WEINBERG R S，et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes[J] . Leukemia，1993，7(Suppl)1：21-29. [42] WIJERMANS P W，KRULDER J W，HUIJGENS P C，et al. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome[Ｊ] . Leukemia，1997，11(Suppl)1：S19-23. [43] CUNNINGHAM T J，NEMOTO T，ROSNER D，et al. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271)[J] .Cancer Chemother Rep，1974，58(5 Pt 1)：677-681. [44] BELLET R E，MASTRANGELO M J，ENGSTROM P F，et al. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816)[Ｊ] .Cancer Chemother Rep，1974，58(2)：217-222. [45] WEISS A J，STAMBAUGU L F，MASTRANGELO M J，et al. Phase I study of 5-azacytidine[Ｊ] .Cancer Chemother Rep，1972，56：413-419. [46] SESSA C，TEN B，HUININK W，et al. Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian carcinoma[J] .Eur J Cancer，1990，26(2)：137-138. [47] WEISS A J，METTER G E，NEALON T F，et al. Phase II study of 5-azacytidine in solid tumors[Ｊ] .Cancer Treat Rep，1977，61(1)：55-58. [48] ABELE R，CLAVEL M，DODION P，et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal，head and neck，renal carcinomas and malignant melanomas[Ｊ] . Eur J Cancer Clin Oncol，1987，23(12)：1921-1924. [49] MOMPARLER R L，BOUFFARD D Y，MOMPARLER L F，et al. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer[Ｊ] . Anticancer Drugs，1997，8(4)：358-368. [50] THIBAULT A，FIGG W D，BERGAN R C，et al. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer[Ｊ] . Tumori，1998，84(1)：87-89. [51] BAHAR A，BICKNELL J E，SIMPSON D J，et al. Loss of expression of the growth inhibitory gene GADD45gamma，in human pituitary adenomas，is associated with CpG island methylation[Ｊ] . Oncogene，2004，23(4)：936-944. [52] ALLEMAN W G，TABIOS R L，CHANDRAMOULI G V，et al. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clearcell renal carcinoma with 5-aza-2′-deoxycytidine[Ｊ] . Clin Cancer Res，2004，10(20)：7011-7021. [53] MIOTTO E，SABBIONI S，VERONESE A，et al. Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer[Ｊ] .Cancer Res，2004，64(22)：8156-8519. [54] KAWAKAMI T，SHIINA H，IGAWA M，et al. Inactivation of the hMSH3 mismatch repair gene in bladder cancer[Ｊ] . Biochem Biophys Res Commun，2004，325(3)：934-942. [55] RAMCHANDANI S，MACLEOD A R，PINARD M，et al. Inhibition of tumorigenesis by a cytosine-DNA，methyltransferase，antisense oligodeoxynucleotide[Ｊ] . Proc Natl Acad Sci USA，1997，94(2)：684-689. [56] DOWNWARD J. RNA interference[J] .BMJ，2004，328(7450)：1245-1248.